Pharmaceutical

Zai Lab and Pfizer to commercialise XACDURO in China

Zai Lab and Pfizer have entered a strategic collaboration for the commercialisation of XACDURO in mainland China.

Nov 23, 2024 - 06:00
Zai Lab and Pfizer to commercialise XACDURO in China
Zai Lab and Pfizer have entered a strategic collaboration for the commercialisation of XACDURO in mainland China.
Read the original article

Tags:

Previous Article

Amneal files again for FDA approval of first dihydroergotamine autoinjector

Next Article

Magazine: Pharma’s green shift with dry powder inhalers

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

ImmunoPrecise touts potential of rabbit monoclonal antibodies in oncology

ImmunoPrecise touts potential of rabbit monoclonal anti...

Oct 22, 2024

Morning Rounds: Americans’ health is trending downward, poll finds

Morning Rounds: Americans’ health is trending downward,...

Dec 15, 2023

FDA approves the first Tysabri biosimilar for MS and Crohn’s disease

FDA approves the first Tysabri biosimilar for MS and Cr...

Aug 26, 2023